ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 998,02
0,06%
Dow Jones
38 571,03
-0,30%
DAX
18 608,16
0,68%
Brent Oil
78,14
-3,30%
Bitcoin
68 763,90
1,50%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Recursion Pharmaceuticals Inc (RXRX)

  7. Recursion Pharmaceuticals Inc (RXRX) Actualités

RXRX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RXRX
DateHeureSourceTitreSymboleSociété
04/06/202400h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
03/06/202415h00GlobeNewswire Inc.Recursion to Participate in Upcoming Investor ConferencesNASDAQ:RXRXRecursion Pharmaceuticals Inc
30/05/202422h03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
29/05/202421h27GlobeNewswire Inc.Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing ToolNASDAQ:RXRXRecursion Pharmaceuticals Inc
24/05/202422h35Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RXRXRecursion Pharmaceuticals Inc
24/05/202422h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
24/05/202422h30GlobeNewswire Inc.Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the BoardNASDAQ:RXRXRecursion Pharmaceuticals Inc
13/05/202411h00GlobeNewswire Inc.Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical IndustryNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/05/202422h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
09/05/202422h01GlobeNewswire Inc.Recursion Provides Business Updates and Reports First Quarter 2024 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
02/05/202414h00GlobeNewswire Inc.Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9NASDAQ:RXRXRecursion Pharmaceuticals Inc
30/04/202414h00GlobeNewswire Inc.Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering ProgramNASDAQ:RXRXRecursion Pharmaceuticals Inc
16/04/202414h00GlobeNewswire Inc.Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerNASDAQ:RXRXRecursion Pharmaceuticals Inc
02/04/202414h00GlobeNewswire Inc.Recursion to Participate in Upcoming Investor ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
26/03/202413h00GlobeNewswire Inc.Recursion Publishes Annual Environmental, Social and Governance ReportNASDAQ:RXRXRecursion Pharmaceuticals Inc
11/03/202409h00GlobeNewswire Inc.Recursion Announces Plans to Open New Office in LondonNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/03/202420h58GlobeNewswire Inc.Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease CommunityNASDAQ:RXRXRecursion Pharmaceuticals Inc
29/02/202414h25Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RXRXRecursion Pharmaceuticals Inc
27/02/202422h05GlobeNewswire Inc.Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/02/202413h59GlobeNewswire Inc.Recursion to Host Public L(earnings) Call on February 27NASDAQ:RXRXRecursion Pharmaceuticals Inc
12/02/202418h21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
29/01/202422h00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RXRXRecursion Pharmaceuticals Inc
24/01/202415h00GlobeNewswire Inc.Altitude Lab Startups Raise Over $120M in CapitalNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/01/202416h59GlobeNewswire Inc.Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
04/01/202413h59GlobeNewswire Inc.Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery PipelineNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/12/202313h59GlobeNewswire Inc.Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery IndustryNASDAQ:RXRXRecursion Pharmaceuticals Inc
15/12/202314h38Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
09/11/202315h41GlobeNewswire Inc.Bayer and Recursion Focus Research Collaboration on OncologyNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/11/202314h01GlobeNewswire Inc.Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision OncologyNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/11/202313h58GlobeNewswire Inc.Recursion Provides Business Updates and Reports Third Quarter 2023 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RXRX

Dernières Valeurs Consultées

USOTC
YEWTF
Environmental Waste (PK)
BIT
1HOOD
Robinhood Markets
DBI
I2VJ
WKN A30AF5
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés